Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Kazuteru Mitsuhashi"'
Autor:
Hanako Nakajima, Hiroshi Okada, Akinori Kogure, Takafumi Osaka, Takeshi Tsutsumi, Toru Tanaka, Goji Hasegawa, Shinichi Mogami, Kazuteru Mitsuhashi, Noriyuki Kitagawa, Yoshitaka Hashimoto, Miho Yano, Muhei Tanaka, Akane Kitamura, Michiyo Ishii, Naoto Nakamura, Akio Kishi, Emi Ushigome, Masahide Hamaguchi, Michiaki Fukui
Publikováno v:
Diabetology, Vol 3, Iss 4, Pp 620-633 (2022)
Nocturia is a common disease in patients with type 2 diabetes mellitus that can reduce the quality of life. Sodium glucose co-transporter 2 (SGLT2) inhibitors increase the urine volume and are often discontinued when polyuria occurs, although tofogli
Externí odkaz:
https://doaj.org/article/b87cbad1350342ff9d6a3e3206f6e382
Autor:
Masahide Hamaguchi, Yoshitaka Hashimoto, Toru Tanaka, Goji Hasegawa, Michiyo Ishii, Hiroshi Okada, Kazuteru Mitsuhashi, Noriyuki Kitagawa, Emi Ushigome, Masahiro Yamazaki, Michiaki Fukui
Publikováno v:
Clinical Medicine Insights: Endocrinology and Diabetes, Vol 14 (2021)
Background: The safe method of instructing insulin dose reduction in combination with SGLT2 inhibitors, dapagliflozin for patients with type 1 diabetes mellitus has not been clarified. In this study, we conducted a stratified, 2-arm, parallel compara
Externí odkaz:
https://doaj.org/article/0615c11ebecb4150a040c7771f4ce9a2
Autor:
Masahide, Hamaguchi, Yuta, Yoshimura, Hanako, Nakajima, Toru, Tanaka, Goji, Hasegawa, Michiyo, Ishii, Hiroshi, Okada, Kazuteru, Mitsuhashi, Noriyuki, Kitagawa, Takuro, Okamura, Yoshitaka, Hashimoto, Saori, Majima, Takafumi, Senmaru, Emi, Ushigome, Naoko, Nakanishi, Mai, Asano, Masahiro, Yamazaki, Michiaki, Fukui
Publikováno v:
Journal of clinical biochemistry and nutrition. 71(2)
To clarify the frequency of hypoglycemia in patients with type 1 diabetes mellitus receiving dapagliflozin combination therapy to reduce their basal insulin dose. Sixty subjects were assigned to two groups according to their basal insulin-to-total da
Autor:
Kazuteru Mitsuhashi, Michiyo Ishii, Goji Hasegawa, Masahiro Yamazaki, Noriyuki Kitagawa, Michiaki Fukui, Toru Tanaka, Masahide Hamaguchi, Hiroshi Okada
Publikováno v:
Diabetes. 70
Background and Objective: The safe method of instructing insulin dose reduction in combination with SGLT2 inhibitors, dapagliflozin for patients with type 1 diabetes mellitus has not been clarified. In this study, we conducted a stratified, two-arm,
Autor:
Masahide Hamaguchi, Yoshitaka Hashimoto, Toru Tanaka, Goji Hasegawa, Michiyo Ishii, Hiroshi Okada, Kazuteru Mitsuhashi, Noriyuki Kitagawa, Emi Ushigome, Masahiro Yamazaki, Michiaki Fukui
Background: The sodium–glucose cotransporter 2 (SGLT2) inhibitor combined with insulin is a novel therapy for type 1 diabetes mellitus. Without reducing basal insulin, hypoglycemia could occur frequently in this therapy. However, ketoacidosis is an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::78a8b5b9e067240c9bc4ebc33228286c
https://doi.org/10.21203/rs.3.rs-52292/v3
https://doi.org/10.21203/rs.3.rs-52292/v3
Autor:
Masahide Hamaguchi, Yoshitaka Hashimoto, Toru Tanaka, Goji Hasegawa, Michiyo Ishii, Hiroshi Okada, Kazuteru Mitsuhashi, Noriyuki Kitagawa, Emi Ushigome, Masahiro Yamazaki, Michiaki Fukui
Background SGLT2 inhibitor combined with insulin is a novel therapy for patients with type 1 diabetes mellitus. Without the reduction of basal insulin, hypoglycemia could occur frequently in this therapy. However, ketoacidosis is an undesirable adver
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6e7f54f1bdc641899aefdfad5803a118
https://doi.org/10.21203/rs.3.rs-52292/v2
https://doi.org/10.21203/rs.3.rs-52292/v2
Autor:
Masahide Hamaguchi, Yoshitaka Hashimoto, Toru Tanaka, Goji Hasegawa, Michiyo Ishii, Hiroshi Okada, Kazuteru Mitsuhashi, Noriyuki Kitagawa, Emi Ushigome, Masahiro Yamazaki, Michiaki Fukui
Background: SGLT2 inhibitor combined with insulin therapy is a novel therapy for patients with type 1 diabetes mellitus. Without the reduction of basal insulin, hypoglycemia could occur frequently in this therapy. But diabetic ketoacidosis is an unde
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85a0bb750d14963886ba8a240339af64
https://doi.org/10.21203/rs.3.rs-52292/v1
https://doi.org/10.21203/rs.3.rs-52292/v1
Autor:
Masahiro Yamazaki, Noriyuki Kitagawa, Michiaki Fukui, Michiyo Ishii, Yoshitaka Hashimoto, Hiroshi Okada, Goji Hasegawa, Masahide Hamaguchi, Toru Tanaka, Kazuteru Mitsuhashi, Emi Ushigome
Publikováno v:
Clinical Medicine Insights: Endocrinology and Diabetes, Vol 14 (2021)
Clinical Medicine Insights. Endocrinology and Diabetes
Clinical Medicine Insights. Endocrinology and Diabetes
Background: The safe method of instructing insulin dose reduction in combination with SGLT2 inhibitors, dapagliflozin for patients with type 1 diabetes mellitus has not been clarified. In this study, we conducted a stratified, 2-arm, parallel compara
Autor:
Kazuteru Mitsuhashi, Takafumi Senmaru, Takuya Fukuda, Masahiro Yamazaki, Katsuhiko Shinomiya, Morio Ueno, Shigeru Kinoshita, Jo Kitawaki, Masato Katsuyama, Muneo Tsujikawa, Hiroshi Obayashi, Naoto Nakamura, Michiaki Fukui
Publikováno v:
Endocrine. 51:174-184
Decreases in serum testosterone concentrations in aging men are associated with metabolic disorders. Testosterone has been reported to increase GLUT4-dependent glucose uptake in skeletal muscle cells and cardiomyocytes. However, studies on glucose up
Autor:
Takao Kojima, Akihiro Obora, Michiaki Fukui, Masahide Hamaguchi, Takuya Fukuda, Yoshitaka Hashimoto, Kazuteru Mitsuhashi
Publikováno v:
Endocrine journal. 64(11)
Fatty liver disease and metabolic syndrome (MetS) are both shown to increase the risk of type 2 diabetes. The aim of this study was to investigate the combined effect of fatty liver and MetS on incident diabetes. In this cohort study of 17,810 partic